Barclays PLC Acadia Pharmaceuticals Inc Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Barclays PLC holds 277,565 shares of ACAD stock, worth $4.52 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

277,565

Previous 277,565 -0.0%

Holding current value

$4.52 Million

Previous $4.27 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$15.14 - $19.14 $2.34 Million - $2.96 Million	154,854 Added 126.19%	277,565 $4.27 Million
Q2 2024 Aug 14, 2024	SELL	$14.62 - $18.42 $133,524 - $168,229	-9,133 Reduced 6.93%	122,711 $1.99 Million
Q1 2024 May 15, 2024	SELL	$17.79 - $30.86 $3.82 Million - $6.63 Million	-214,959 Reduced 61.98%	131,844 $2.44 Million
Q4 2023 Feb 15, 2024	BUY	$20.78 - $31.77 $2.69 Million - $4.12 Million	129,533 Added 59.62%	346,803 $10.9 Million
Q3 2023 Nov 07, 2023	BUY	$20.84 - $33.47 $577,893 - $928,123	27,730 Added 14.63%	217,270 $4.53 Million
Q2 2023 Aug 03, 2023	BUY	$17.8 - $25.65 $424,743 - $612,060	23,862 Added 14.4%	189,540 $4.54 Million
Q1 2023 May 04, 2023	SELL	$16.32 - $20.92 $2.38 Million - $3.04 Million	-145,531 Reduced 46.76%	165,678 $3.12 Million
Q4 2022 Feb 13, 2023	SELL	$14.2 - $18.63 $224,899 - $295,061	-15,838 Reduced 4.84%	311,209 $4.95 Million
Q3 2022 Nov 03, 2022	BUY	$14.11 - $18.27 $3.13 Million - $4.05 Million	221,781 Added 210.69%	327,047 $5.35 Million
Q2 2022 Aug 12, 2022	BUY	$13.01 - $27.22 $380,932 - $797,001	29,280 Added 38.53%	105,266 $1.48 Million
Q1 2022 May 16, 2022	SELL	$20.94 - $27.5 $1.81 Million - $2.37 Million	-86,352 Reduced 53.19%	75,986 $1.84 Million
Q4 2021 Feb 14, 2022	BUY	$16.79 - $27.09 $997,090 - $1.61 Million	59,386 Added 57.68%	162,338 $3.79 Million
Q3 2021 Nov 09, 2021	BUY	$15.78 - $24.77 $316,373 - $496,613	20,049 Added 24.18%	102,952 $1.71 Million
Q2 2021 Aug 13, 2021	BUY	$19.4 - $27.42 $283,705 - $400,990	14,624 Added 21.42%	82,903 $2.02 Million
Q1 2021 May 13, 2021	BUY	$25.02 - $54.99 $657,900 - $1.45 Million	26,295 Added 62.63%	68,279 $1.76 Million
Q4 2020 Feb 11, 2021	SELL	$41.04 - $56.79 $636,817 - $881,210	-15,517 Reduced 26.99%	41,984 $2.25 Million
Q3 2020 Nov 12, 2020	SELL	$36.42 - $57.0 $3.91 Million - $6.12 Million	-107,362 Reduced 65.12%	57,501 $2.37 Million
Q2 2020 Aug 12, 2020	BUY	$39.26 - $52.73 $2.28 Million - $3.06 Million	58,072 Added 54.38%	164,863 $7.99 Million
Q1 2020 May 13, 2020	SELL	$31.65 - $46.87 $4.68 Million - $6.93 Million	-147,754 Reduced 58.05%	106,791 $4.51 Million
Q4 2019 Feb 10, 2020	SELL	$36.21 - $51.4 $1.76 Million - $2.5 Million	-48,733 Reduced 16.07%	254,545 $10.9 Million
Q3 2019 Nov 14, 2019	BUY	$22.22 - $44.01 $4.27 Million - $8.46 Million	192,284 Added 173.24%	303,278 $10.9 Million
Q2 2019 Aug 14, 2019	BUY	$23.32 - $28.12 $150,227 - $181,149	6,442 Added 6.16%	110,994 $2.97 Million
Q1 2019 May 15, 2019	SELL	$16.17 - $27.38 $1.57 Million - $2.65 Million	-96,932 Reduced 48.11%	104,552 $2.81 Million
Q4 2018 Feb 14, 2019	SELL	$14.32 - $22.92 $3.48 Million - $5.57 Million	-243,079 Reduced 54.68%	201,484 $3.26 Million
Q3 2018 Nov 14, 2018	BUY	$13.03 - $21.81 $4.51 Million - $7.55 Million	346,025 Added 351.16%	444,563 $9.23 Million
Q2 2018 Aug 14, 2018	BUY	$15.07 - $22.34 $488,674 - $724,419	32,427 Added 49.05%	98,538 $1.5 Million
Q1 2018 May 15, 2018	SELL	$22.47 - $32.33 $697,468 - $1 Million	-31,040 Reduced 31.95%	66,111 $1.48 Million
Q4 2017 Feb 14, 2018	SELL	$26.84 - $39.14 $1.57 Million - $2.3 Million	-58,660 Reduced 37.65%	97,151 $2.92 Million
Q3 2017 Nov 14, 2017	BUY	$29.49 - $38.37 $4.59 Million - $5.98 Million	155,811	155,811 $5.87 Million

Others Institutions Holding ACAD

# of Institutions

280

Shares Held

156M

Call Options Held

901K

Put Options Held

314K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.63B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account